Ziftomenib KO-539 is a novel therapeutic agent that has generated significant interest in the pharmaceutical industry. This product is a small molecule inhibitor of oncogenic KRAS G12C, a cancer-causing protein that is commonly found in several tumor types. In this article, we will discuss everything you need to know about Ziftomenib KO-539 CAS: 2134675-36-6, including its chemical properties, health benefits, mechanism of action, safety profile, and dosing information.
Introduction: Ziftomenib KO-539 is a small molecule inhibitor that selectively targets the mutant form of KRAS G12C, an oncogenic protein commonly found in several tumor types. This therapeutic agent is a promising new treatment option for patients with KRAS-mutant cancers, including lung, colon, and pancreatic cancer. Ziftomenib KO-539 works by binding to a specific pocket on the mutant KRAS protein, preventing it from functioning correctly and blocking its downstream signaling pathways.
Chemical Properties: The chemical name of Ziftomenib KO-539 is 2-[(2,5-difluorophenyl)amino]-N-[2-[(4-methoxyphenyl)amino]-4-(methylsulfonyl)phenyl]pyrimidine-5-carboxamide. Its molecular formula is C26H22F2N6O4S, and its formula weight is 558.56 g/mol. The CAS number for Ziftomenib KO-539 is 2134675-36-6.
Top Ten Keywords and Synonyms:
- KRAS G12C inhibitor
- Ziftomenib KO-539 clinical trials
- Small molecule targeted therapy
- Mutant KRAS cancer treatment
- KRAS G12C selective inhibitor
- Novel oncology drug
- Pyrimidine-based compound
- Ziftomenib KO-539 mechanism of action
- Antineoplastic agent
- KRAS G12C blocking agent
Health benefits: Ziftomenib KO-539 represents a significant advancement in the treatment of KRAS-mutant cancers, offering patients with this genetic alteration a new therapeutic option. Clinical trials have shown that Ziftomenib KO-539 has potent anti-tumor activity, with promising results in patients with non-small cell lung cancer (NSCLC) and colorectal cancer. In a phase 1/2 clinical trial conducted on NSCLC, Ziftomenib KO-539 demonstrated an overall response rate of 35%, with a median duration of response of 11 months.
Potential effects: Ziftomenib KO-539 has shown promising results in preclinical and clinical trials, with significant potential for use in the treatment of KRAS-mutant cancers. It has been reported that the drug blocks mutant KRAS G12C signaling downstream of RAF, preventing cancer cell proliferation and inducing apoptosis. The drug is also believed to have a direct effect on the tumor microenvironment by reducing the number of tumor-infiltrating myeloid-derived suppressor cells.
Product mechanism: Ziftomenib KO-539 is a selective inhibitor of mutant KRAS G12C, a form of the oncogenic KRAS protein that is commonly found in several tumor types. The drug binds to a specific pocket on the mutant KRAS G12C protein, preventing it from interacting with downstream effector proteins and blocking its downstream signaling pathways. By inhibiting the activity of the oncogenic KRAS G12C protein, Ziftomenib KO-539 suppresses tumor growth and induces apoptosis.
Safety: Ziftomenib KO-539 has been well-tolerated in clinical trials, with no dose-limiting toxicities reported to date. Adverse events have been generally mild and include nausea, vomiting, diarrhea, and fatigue